Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule

Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule

MT newswireMT newswire2026/10/07 17:43

01:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61

01:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Procore director Kevin J. O’Connor disposes of USD 820,090 in common shares

Procore: Director Kevin J. O’Connor reported selling 15,384 common shares on Oct. 5-6. Sales prices ranged from $52.83 to $55.08 per share. Indirect holding fell to 908,286 shares, held via the Kevin J. O’Connor Revocable Trust. O’Connor also reported 21,344 shares held directly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procore Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065378), on October 07, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/08 00:37

Microsoft (MSFT.US) launches new flagship laptop! Equipped with Nvidia chips, certain AI tasks outperform Apple MacBook.

Microsoft held a Surface product launch event on Wednesday, announcing the price and release schedule for the new flagship Surface Laptop Ultra equipped with Nvidia chips. Microsoft also stated that the device outperforms competing Apple products in certain artificial intelligence (AI) tasks.

智通财经•2026/10/08 00:36

Dan Ives reveals top tech stock picks for 2027! Nvidia, Microsoft, Apple, and three other stocks make the list, Tesla selected as “disruptive tech top pick”

Former Wedbush tech analyst Dan Ives released his top picks for the technology sector in 2027 on Wednesday, listing Nvidia, Microsoft, Palantir, Apple, and CrowdStrike as his five top technology choices.

智通财经•2026/10/08 00:11